Drug intelligence / Profile preview

UA007

Development stage: Phase 2
Lead developer: Usynova Pharmaceuticals
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

UA007 is a recombinant human interleukin-1 receptor antagonist developed by Usynova Pharmaceuticals. It is being investigated for the treatment of intermittent gouty arthritis and for preventing chemotherapy-induced diarrhea in patients with colorectal cancer receiving FOLFIRI chemotherapy.

Targets

IL1R1 (Interleukin-1 Receptor Type 1)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))

Beyond the preview

Go deeper on UA007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UA007.